Oppenheimer & Co’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Oppenheimer & Co’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-6,500	Closed	-$609K	–	1610
2021 Q2	$609K	Buy	6,500 +3,077	+90%	+$283K	0.01%	938
2021 Q1	$315K	Buy	3,423 +81	+2%	+$6.83K	0.01%	1151
2020 Q4	$244K	Sell	3,342 -596	-15%	-$44.3K	0.01%	1171
2020 Q3	$306K	Buy	3,938 +45	+1%	+$3.1K	0.01%	971
2020 Q2	$216K	Buy	+3,893	New	+$167K	0.01%	1091
2017 Q1	–	Sell	-16,797	Closed	-$272K	–	1376
2016 Q4	$272K	Sell	16,797 -11,200	-40%	-$203K	0.01%	1038
2016 Q3	$508K	Buy	27,997 +11,300	+68%	+$221K	0.01%	807
2016 Q2	$275K	Hold	16,697	–	–	0.01%	999
2016 Q1	$277K	Buy	16,697 +400	+2%	+$7K	0.01%	972
2015 Q4	$353K	Buy	+16,297	New	+$317K	0.01%	890
2014 Q3	–	Sell	-15,117	Closed	-$239K	–	1525
2014 Q2	$239K	Buy	+15,117	New	+$216K	0.01%	1171

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Oppenheimer & Co's HZNP Position: Q3 2021 in Review

Oppenheimer & Co sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2021, closing a stake of 6,500 shares — an estimated $609K sold.

Oppenheimer & Co first reported a position in HZNP in Q2 2014 and held it in 11 quarters. The position peaked at $609K in Q2 2021. 572 funds tracked by Wall St. Rank hold HZNP as of Q3 2021.

Oppenheimer & Co reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2021 after selling out during the quarter.
Oppenheimer & Co sold 6,500 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2021, an estimated $609K.
Oppenheimer & Co first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2014 and held it in 11 quarters.
Oppenheimer & Co's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $609K in Q2 2021.
572 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2021.

Based on Oppenheimer & Co's 13F filing for Q3 2021, filed 12 Nov 2021.